Solara had put in place robust manufacturing and quality processes to mitigate the risks of N-Nitroso Dimethylamine (NDMA) formation in the Ranitidine HCL API. Subsequent submission of the pertinent data has fast-tracked the restoration of CEP by EDQM. Solara is currently the only company among Ranitidine API manufacturers to have its CEP restored.